Argenx declares Phase 3 win for Vyvgart Hytrulo in autoimmune myositis
Endpoints News reports Argenx announced a Phase 3 win for Vyvgart Hytrulo in autoimmune myositis, setting up a potential next indication nod.
argenx
argenx is a antibodies company covered in the openbionews harvest.
Company Info
Recent News
Argenx preps next potential Vyvgart nod after ph. 3 win
Fierce Pharma reports Argenx is heading to the FDA with Vyvgart for a potential blockbuster autoimmune indication after a Phase 3 win.
Argenx jumps on Phase 3 data for blockbuster Vyvgart
Argenx shares jumped on positive Phase 3 data for its blockbuster drug Vyvgart, reinforcing the drug's growth trajectory.
Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug
Argenx acquires Forte for $2.2B for ph.2-stage vitiligo drug.
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy
Argenx deepens immuno expertise with $2.2B Forte Biosciences buy.